Advertisement.

GLPG Projected Dividend Yield

ADR (Sponsored)/Galapagos NV ( NASDAQ : GLPG )

Galapagos is a biopharmaceutical company engaged in the discovery, development, and commercialization of medicines with modes of action, addressing disease areas of unmet medical need. Co.'s clinical pipeline includes: preferential JAK1 inhibitor filgotinib, which is approved for the treatment of rheumatoid arthritis in Europe and Japan, and in a trial in Crohn's disease; GLPG1205, which is a GPR84 inhibitor that engages in the idiopathic pulmonary fibrosis (IPF) trial with IPF patients; GLPG4716, which is a chitinase inhibitor that engages in preparation for a study in IPF; and Toledo molecule GLPG3970, which is a SIK2/3 inhibitor that engages in Proof of Concept trials.

20 YEAR PERFORMANCE RESULTS

GLPG Dividend History Detail
GLPG Dividend News
GLPG Competitors News

# of Shares: 0

Closing Price: 26.82

Current Market Value: 0.00

Cost Basis: 0.00

Date Acquired:

Dividend Cash Flow
Year	Annual Dividend	Dividend Growth	# of Shares	Annual Dividend Income	Yield On Cost %
2014	0.00	0%	0	$ 0.00	0.00%
2015	0.00	0%	0	$ 0.00	0.00%
2016	0.00	0%	0	$ 0.00	0.00%
2017	0.00	0%	0	$ 0.00	0.00%
2018	0.00	0%	0	$ 0.00	0.00%
2019	0.00	0%	0	$ 0.00	0.00%
2020	0.00	0%	0	$ 0.00	0.00%
2021	0.00	0%	0	$ 0.00	0.00%
2022	0.00	0%	0	$ 0.00	0.00%
2023	0.00	0%	0	$ 0.00	0.00%
2024	0.00	0%	0	$ 0.00	0.00%
2025	0.00	0%	0	$ 0.00	0.00%
Using the current years Dividend Growth rate of 0% and projecting 0% forward the annual dividend income in 10/yrs would be $ 0.00 with a yield on cost % of 0.00%
Rolling Last 4 qtrs dividends total $ 0.00 and Previous last 4 qtrs dividends total $ 0.00
Dividend 1 Yr Growth = ( 0.00 – 0.00 ) × 100 = 0% (Click the Edit pencil if you want to modify the forward dividend growth rate projection) 0.00

Year	Declaration Date	Ex-Dividend Date	Record Date	Payable Date	Dividend $ Amount
Total:					0.0000